DBL™ Adrenaline Injection BP

国: ニュージーランド

言語: 英語

ソース: Medsafe (Medicines Safety Authority)

即購入

製品の特徴 製品の特徴 (SPC)
26-07-2021

有効成分:

Adrenaline acid tartrate 1.8mg equivalent to 1:1000 or 1 mg/mL Adrenaline

から入手可能:

Pfizer New Zealand Limited

INN(国際名):

Adrenaline acid tartrate 1.8 mg (Equiv to 1:1000 or 1 mg/mL Adrenaline)

投薬量:

1:1000

医薬品形態:

Solution for injection

構図:

Active: Adrenaline acid tartrate 1.8mg equivalent to 1:1000 or 1 mg/mL Adrenaline Excipient: Sodium chloride Sodium metabisulfite Water for injection

パッケージ内のユニット:

Ampoule, glass, 5 x 1mL, 5 mL

クラス:

Restricted

処方タイプ:

Restricted

製:

Boehringer Ingelheim Pharma GmbH & Co KG

適応症:

For the treatment of acute allergic reactions, life-threatening angioneurotic oedema, and anaphylactic shock resulting from reactions to drugs, animal serums, insect stings and other allergens.

製品概要:

Package - Contents - Shelf Life: Ampoule, glass, 5 x 1mL - 5 mL - 24 months from date of manufacture stored at or below 25°C - Ampoule, glass, 50 x 1mL - 50 mL - 24 months from date of manufacture stored at or below 25°C

承認日:

1984-03-08

製品の特徴

                                Version: pfdadrni10721
Supersedes: pfdadrni10219
Page 1 of 11
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
DBL™ Adrenaline 1:1000 (1 mg/mL) and 1:10,000 (1 mg/10 mL) solution
for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
DBL Adrenaline 1:1000 (1 mg/mL) and 1:10,000 (1 mg/10 mL) solution for
injection is a
sterile, clear, colourless aqueous solution.
Each ampoule of DBL Adrenaline Injection 1:1,000 contains 1.8 mg of
adrenaline acid tartrate
(equivalent to 1 mg of adrenaline)/mL of water.
Each ampoule of DBL Adrenaline Injection 1:10,000 contains 1.8 mg of
adrenaline acid
tartrate (equivalent to 1 mg of adrenaline)/10 mL of water.
EXCIPIENT(S) WITH KNOWN EFFECT
Each ampoule contains 1 mg/mL of sodium metabisulfite and 8 mg/mL of
sodium chloride.
For full list of excipients, see Section 6.1 List of excipients.
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS
DBL ADRENALINE 1:1,000
For the treatment of acute allergic reactions, life-threatening
angioneurotic oedema and
anaphylactic shock resulting from reactions to drugs, animal serums,
insect stings and other
allergens.
DBL ADRENALINE 1:10,000
Adjunctive use in the management of cardiac arrest and anaphylactic
shock resulting from
reactions to drugs, animal serums, insect stings and other allergens.
4.2 DOSE AND METHOD OF ADMINISTRATION
DBL Adrenaline injection does not contain any preservatives. It is for
single use in one patient
only. Discard any residue.
Do not use if the injection is brown or contains a precipitate.
Version: pfdadrni10721
Supersedes: pfdadrni10219
Page 2 of 11
Adrenaline is given by subcutaneous injection. It may also be
administered intramuscularly but
not into the buttocks.
In extreme emergencies, where a more rapid effect is required,
adrenaline may be given by
slow intravenous injection or by slow intravenous infusion but
ONLY AS A DILUTE SOLUTION (1 IN
10,000 OR 1 IN 100,000).
ACUTE ALLERGIC REACTIONS, LIFE-THREATENING ANGIONEUROTIC OEDEMA AND
ANAPHYLACTIC SHOCK
DBL ADRENALINE 1:1
                                
                                完全なドキュメントを読む
                                
                            

ドキュメントの履歴を表示する